Samsung Biologics Co Stock EBITDA
| 207940 Stock | 929,000 29,000 3.03% |
Samsung Biologics Co fundamentals help investors to digest information that contributes to Samsung Biologics' financial success or failures. It also enables traders to predict the movement of Samsung Stock. The fundamental analysis module provides a way to measure Samsung Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Samsung Biologics stock.
Samsung |
Samsung Biologics Co Company EBITDA Analysis
Samsung Biologics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Samsung Biologics EBITDA | 737.78 B |
Most of Samsung Biologics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Samsung Biologics Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Samsung Biologics Co reported earnings before interest,tax, depreciation and amortization of 737.78 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The ebitda for all Republic of Korea stocks is significantly lower than that of the firm.
Samsung EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Samsung Biologics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Samsung Biologics could also be used in its relative valuation, which is a method of valuing Samsung Biologics by comparing valuation metrics of similar companies.Samsung Biologics is currently under evaluation in ebitda category among its peers.
Samsung Fundamentals
| Return On Equity | 0.0751 | |||
| Return On Asset | 0.0422 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 58.92 T | |||
| Shares Outstanding | 71.17 M | |||
| Shares Owned By Insiders | 75.18 % | |||
| Shares Owned By Institutions | 13.80 % | |||
| Price To Book | 6.92 X | |||
| Price To Sales | 23.45 X | |||
| Revenue | 1.57 T | |||
| Gross Profit | 723.35 B | |||
| EBITDA | 737.78 B | |||
| Net Income | 393.59 B | |||
| Total Debt | 1.11 T | |||
| Cash Flow From Operations | 454.6 B | |||
| Earnings Per Share | 2,418 X | |||
| Target Price | 1000000.0 | |||
| Number Of Employees | 10 | |||
| Beta | 0.58 | |||
| Market Capitalization | 57.3 T | |||
| Total Asset | 7.97 T | |||
| Z Score | 30.6 | |||
| Net Asset | 7.97 T |
About Samsung Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Samsung Biologics Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Samsung Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Samsung Biologics Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Samsung Biologics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Samsung Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Samsung Biologics will appreciate offsetting losses from the drop in the long position's value.Moving together with Samsung Stock
The ability to find closely correlated positions to Samsung Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Samsung Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Samsung Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Samsung Biologics Co to buy it.
The correlation of Samsung Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Samsung Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Samsung Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Samsung Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Samsung Stock
Samsung Biologics financial ratios help investors to determine whether Samsung Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Samsung with respect to the benefits of owning Samsung Biologics security.